This website is intended for US Healthcare Professionals.

CONTact Your MSL
Back to Congresses

EHA 2024

  • June 13 -
  • 16, 2024
  •  |
  • Madrid, Spain

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

Poster
Oral ARV-393 is a BCL6 Degrading PROTAC® Efficacious as a Monotherapy in B-Cell Lymphoma Preclinical CDX and PDX Models
SM Gough et al.
View Material

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

YES, I AM AN HCP

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.

I AM NOT AN HCP